Vyera immediately raised the list price from $17.50 to $750 per tablet, which significantly impacted access to care. The complaint, which the FTC filed jointly with the New York State Office of the Attorney General, alleges that when Vyera acquired Daraprim, the drug had been an affordable, life-saving treatment for more than 60 years. “Vyera kept the price of Daraprim astronomically high by illegally boxing out the competition.” “Daraprim is a lifesaving drug for vulnerable patients,” said Gail Levine, Deputy Director of the Bureau of Competition at the Federal Trade Commission. But for those with compromised immune systems-such as individuals with HIV/AIDS, cancer patients, or recipients of organ transplants-toxoplasmosis can lead to deadly infections of the brain and lungs. In most people, toxoplasmosis is easily contained by the immune system and causes no symptoms, according to the complaint. The Federal Trade Commission has filed a complaint in federal court against Vyera Pharmaceuticals, LLC, alleging an elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug, Daraprim.ĭaraprim is the gold standard treatment for a rare, potentially fatal parasitic infection known as toxoplasmosis. About the FTC Show/hide About the FTC menu items.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |